Precision medicine and renal cell carcinoma : current situation and the future
The prevalence of renal cell carcinoma is increasing in recent years. With the development of research, we know more about the mechanism and biological characteristics of renal cell carcinoma. Currently, the most used prognosis evaluation methods are clinical factors based prognostic prediction models. New drugs, typified by the checkpoint inhibitors, have achieved great success in the treatment of renal cell carcinoma, on the basis of traditional tyrosine kinase inhibitor. With recognition of more prognosis and treatment related biomarkers, directive role for the prognosis prediction and treatment options could be expected.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Zhonghua yi xue za zhi - 101(2021), 46 vom: 14. Dez., Seite 3767-3770 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Gong, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.12.2021 Date Revised 14.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112137-20210721-01622 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334319056 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334319056 | ||
| 003 | DE-627 | ||
| 005 | 20231225223445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112137-20210721-01622 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334319056 | ||
| 035 | |a (NLM)34895414 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Gong, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision medicine and renal cell carcinoma |b current situation and the future |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The prevalence of renal cell carcinoma is increasing in recent years. With the development of research, we know more about the mechanism and biological characteristics of renal cell carcinoma. Currently, the most used prognosis evaluation methods are clinical factors based prognostic prediction models. New drugs, typified by the checkpoint inhibitors, have achieved great success in the treatment of renal cell carcinoma, on the basis of traditional tyrosine kinase inhibitor. With recognition of more prognosis and treatment related biomarkers, directive role for the prognosis prediction and treatment options could be expected | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Tang, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, J C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 101(2021), 46 vom: 14. Dez., Seite 3767-3770 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2021 |g number:46 |g day:14 |g month:12 |g pages:3767-3770 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112137-20210721-01622 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2021 |e 46 |b 14 |c 12 |h 3767-3770 | ||